Acute toxicity and anti-dyslipidemic activity of Arogyavardhini compound in fructose-induced dyslipidemia in albino rats

Padhar, Bharatkumar C; Dave, Alankruta R; Nariya, Mukeshkumar

Abstract

Metabolic syndrome is a co-occurrence of obesity, insulin resistance, hypertension, and dyslipidemia caused by improper diet and lifestyle. Arogyavardhini compound (AVC) contains an equal quantity of Arogyavardhini rasa and Lasuna powder. In clinical practice, Arogyavardhini Rasa is well known for its antidyslipidemic and weight lowering effect. Therefore, the present experimental study was designed to evaluate the safety of AVC on acute administration and anti-dyslipidemic activity in albino rats. An acute oral toxicity study for AVC was carried out by following OECD 425 guidelines. The anti-dyslipidemic activity was carried out against fructose-induced dyslipidemia in albino rats. No mortality and toxicity were observed and gross behaviours of all the albino rats were found normal during the experimental period of 14 days in the acute toxicity study. Fructose significantly increased blood sugar, triglycerides, SGPT, and alkaline phosphatase levels in albino rats in comparison to the control group. AVC treated group produced a decrease in serum triglyceride, transaminases, and alkaline phosphatase, which suggest that the drug has potential as anti-dyslipidemic and may be protective for degenerative changes produced by fructose in the liver, kidney, and heart of albino rats. From the present study it is concluded that AVC is safe up to an oral dose of 2000 mg/kg in albino rats and has exhibited a protective role in fructose-induced dyslipidemia in albino rats, hence may be useful in metabolic syndrome.


Keyword(s)

Acute toxicity; Antidyslipidemic activity; Arogyavardhini compound; Fructose; Metabolic syndrome.


Full Text: PDF (downloaded 295 times)

Refbacks

  • There are currently no refbacks.
This abstract viewed 469 times